Siemens Healthineers' fourth-quarter sales up, profit down

Headline results for the fourth quarter:


3.7 billion euros ($4.2 billion)



627 million euros ($713 million)


Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

"We have delivered what we promised and achieved our goals for revenue growth and profit margin. We made the year of the successful IPO also a successful fiscal year for Siemens Healthineers and underpinned our strong competitive position," remarked CEO Bernd Montag. "Thanks to the strength of our portfolio in all segments and the significantly accelerated delivery of the Atellica Solution laboratory diagnostics system, we can look forward with confidence to the 2019 fiscal year," he added.

Other results:

  • Imaging segment sales: 2.2 billion euros ($2.5 billion), up 3 percent, with a significant increase in ultrasound, computed tomography and x-ray products, and "very strong growth in the US"
  • Diagnostics segment sales: 1.1 billion euros ($1.3 billion), down 1 percent, with growth mainly coming from Asia, Australia, Americas, with "Atellica Solution ramp-up on track with 990+ analysers shipped"  
  • Advanced therapies segment sales: 407 million euros ($464 million), up 2 percent, driven by Asia, Australia and Americas
  • Full-year revenue: 13.4 billion euros ($15.3 billion), down 2 percent  

Looking ahead:

Siemens Healthineers expects fiscal year 2019 comparable revenue growth to be in the range of 4 percent to 5 percent year-on-year, while earnings per share are expected to be 20 percent to 30 percent above the level of fiscal year 2018. The company noted that its outlook assumes that "current foreign exchange rates persist for all of fiscal year 2019."

Did you like this article?